BELLUS Health Inc.

TSX:BLU Lagerbericht

Marktkapitalisierung: CA$2.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for BELLUS Health.

Wichtige Informationen

46.1%

Wachstumsrate der Gewinne

41.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum39.0%
Wachstumsrate der Einnahmen69.0%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert16 Jun 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16
BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

May 05
We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Jan 06
Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Sep 10
Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Gewinn- und Umsatzwachstumsprognosen

TSX:BLU - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202540-147-110-643
12/31/20240-141-130-1273
12/31/20230-117-125-1012
3/31/20230-87-89-89N/A
12/31/20220-76-77-77N/A
9/30/20220-73-68-68N/A
6/30/20220-71-64-64N/A
3/31/20220-70-60-60N/A
12/31/20210-71-61-61N/A
9/30/20210-64-49-49N/A
6/30/20210-47-40-40N/A
3/31/20210-37-36-36N/A
12/31/20200-32-30-30N/A
9/30/20200-34-30-30N/A
6/30/20200-35-32-32N/A
3/31/20200-33-29-29N/A
12/31/20190-26-21-21N/A
9/30/20190-18-14-14N/A
6/30/20190-14-9-9N/A
3/31/20190-9-8-8N/A
12/31/20180-7-7-7N/A
9/30/20180-6-7-7N/A
6/30/20180-5-6-6N/A
3/31/20180-4-5-5N/A
12/31/20170-1-5-3N/A
9/30/20170-1-4-3N/A
6/30/201710-3-2N/A
3/31/201710-3-2N/A
12/31/20161-2N/A-2N/A
9/30/20163-1N/A-2N/A
6/30/201630N/A-2N/A
3/31/201630N/A-2N/A
12/31/201530N/A-2N/A
9/30/201520N/A-2N/A
6/30/20152-1N/A-2N/A
3/31/20152-1N/A-2N/A
12/31/20142-2N/A-3N/A
9/30/20142-2N/A-3N/A
6/30/20142-1N/A-4N/A
3/31/20142-1N/A-3N/A
12/31/20132-1N/A-3N/A
9/30/20132-1N/A-3N/A
6/30/20132-2N/A-3N/A
3/31/20132-10N/A-3N/A
12/31/20122-13N/A-3N/A
9/30/20123-15N/A-2N/A
6/30/20123-14N/A-2N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BLU is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: BLU is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: BLU is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: BLU's revenue (69% per year) is forecast to grow faster than the Canadian market (5.3% per year).

Hohe Wachstumseinnahmen: BLU's revenue (69% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if BLU's Return on Equity is forecast to be high in 3 years time

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y